Questions?
Request a Medical Science Liaison (MSL)
Questions?
Request a Medical Science Liaison (MSL)
This guide helps you set goals and expectations with patients who are starting treatment with UPTRAVI. It can be used as a conversation tool and is available to patients to help them stay on treatment by tracking and sharing how they’re feeling with their healthcare team.
Start your patients on UPTRAVI
REVIEW DOSING
Clicking CONTINUE below will take you to the selected site, the content for which Johnson & Johnson is not responsible and to which this Privacy Policy does not apply. We encourage you to read the Privacy Policy of every online service you visit.
The following form is intended for use with patients who are eligible for VA benefits only.
GRIPHON is the largest adult PAH pivotal trial, studied as monotherapy, dual therapy (ERA or PDE5i), and triple therapy (ERA + PDE5i)1,2
UPTRAVI
(selexipag): n=574
Placebo:
n=582
Mean age:
48 years
Female:
80%
Longest endpoint evaluation period of any prostacyclin pathway therapy
Median time from PAH diagnosis in patients taking UPTRAVI
This article includes information that has not been approved by the Food and Drug Administration for UPTRAVI. Please see full Prescribing Information available on this website. Authors[s] of this article have received remuneration from Actelion Pharmaceuticals US, Inc., or its affiliates.
